These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6894012)

  • 1. [The effect of pirenzepine (LS 519) on basal and pentagastrin-stimulated gastric acid secretion in normal persons].
    Galmiche JP; Lerebours E; Colin R
    Med Chir Dig; 1980; 9(4):331-4. PubMed ID: 6894012
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisecretory activity of pirenzepine versus cimetidine in man: a controlled study.
    Procacciante F; Citone G; Montesani C; Ribotta G
    Gut; 1984 Feb; 25(2):178-82. PubMed ID: 6546371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cimetidine and pirenzepine on peroperative electrical vagal stimulation of gastric acid secretion.
    Fritsch WP; Schacht U; Scholten T; Hengels KJ; Mueller J; Strasser K
    Scand J Gastroenterol Suppl; 1980; 66():95-100. PubMed ID: 6941381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of intravenous pirenzepine on gastric acid and pepsin in man.
    el-Sabbagh HN; Prinz RA; Welbourn RB; Baron JH
    Scand J Gastroenterol Suppl; 1980; 66():73-7. PubMed ID: 6787694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the action of pirenzepine and L-hyoscyamine on gastric acid secretion and other muscarinic effects.
    Jaup BH; Stockbrügger RW; Dotevall G
    Scand J Gastroenterol Suppl; 1980; 66():89-94. PubMed ID: 6941380
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of pentagastrin and insulin-stimulated gastric secretion by pirenzepine in healthy and duodenal ulcer subjects.
    Bianchi Porro G; Prada A; Petrillo M; Grossi M
    Scand J Gastroenterol Suppl; 1979; 57():63-7. PubMed ID: 396660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibition of vagal stimulated acid secretion by pirenzepine and cimetidine.
    Scholten T; Fritsch WP; Müller JE; Hengels KJ
    Scand J Gastroenterol Suppl; 1982; 72():169-71. PubMed ID: 6957986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-ulcer and secretion-inhibitory properties of the tricyclic derivative doxepin in rats and dogs.
    Leitold M; Fleissig W; Merk A
    Arzneimittelforschung; 1984; 34(4):468-73. PubMed ID: 6547610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of pirenzepin on the pH of the gastric content and on basal acid secretion and on that stimulated by betazole, in patients with duodenal ulcer].
    Ribeiro Tde C; Coelho LG; Avelar CD; Castro Lde P
    AMB Rev Assoc Med Bras; 1984; 30(5-6):105-7. PubMed ID: 6333050
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of pirenzepine on basal gastric acid and pepsin secretion and on secretion stimulated with graded doses of pentagastrin in duodenal ulcer patients.
    Meneghelli UG; Troncon LE
    Braz J Med Biol Res; 1988; 21(4):781-9. PubMed ID: 3149202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of prolonged treatment of pirenzepine 2HCl on gastric secretion and plasma gastrin levels in rats.
    Okabe S; Tabata K; Kawakami M
    Arzneimittelforschung; 1982; 32(6):664-8. PubMed ID: 6896823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pirenzepine on meal-stimulated acid secretion and gastrin release in normal man.
    Mignon M; Vatier J; Bauer P; Bonfils S
    Scand J Gastroenterol Suppl; 1982; 72():145-51. PubMed ID: 6753112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pirenzepine on basal, pentagastrin- and insulin-stimulated gastric acid secretion in patients with peptic ulcer disease.
    Jaup BH; Stockbrügger R; Dotevall G
    Scand J Gastroenterol; 1979; 14(5):621-4. PubMed ID: 493866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of esaprazole activity on basal gastric secretion and on pentagastrin-stimulated secretion in healthy volunteers.
    Erembourg L; Reggiani P; Tosi GP; Ferla G; Beinat L
    Int J Clin Pharmacol Res; 1987; 7(2):95-100. PubMed ID: 3583500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of cimetidine, pirenzepine and synthetic secretin on stimulated gastric acid secretion].
    Londong W; Londong V; Prechtl R; Schwanner A
    Z Gastroenterol; 1980 Jun; 18(6):306-13. PubMed ID: 6893378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of various secretory inhibitors on peptic activity.
    Gabryelewicz A; Laszewicz W; Sarosiek J
    Scand J Gastroenterol Suppl; 1980; 66():79-85. PubMed ID: 6264587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of gastrin secretion by pirenzepine (LS 519) in treatment of gastric ulcer.
    Tatsuta M; Itoh T; Okuda S; Tamura H; Baba M; Yamamura H
    Scand J Gastroenterol; 1981; 16(2):269-71. PubMed ID: 6895560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of gastric acid secretion by pirenzepine (LS 519) in man.
    Stockbrügger R; Jaup B; Hammer R; Dotevall G
    Scand J Gastroenterol; 1979; 14(5):615-20. PubMed ID: 493865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirenzepine inhibits acid and pepsinogen secretion by the isolated perfused mouse stomach.
    Müller-Lissner SA; Szelenyi I; Engler H; Blum AL
    Scand J Gastroenterol Suppl; 1982; 72():101-3. PubMed ID: 6127794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of inhibition of pentagastrin-stimulated acid secretion on gastric mucosal gland luminal pressure.
    Synnerstad I; Persson AE; Holm L
    Acta Physiol Scand; 1997 May; 160(1):103-11. PubMed ID: 9179318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.